779 A phase 1/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Main Authors: | Aung Naing, Emiliano Calvo, Chen Zhu, Martin Gutierrez, Elena Garralda, Giovanni Abbadessa, Helene Guillemin-Paveau, Meijing Wu, Raymond Perez, Marloes van Dongen, Ferry Eskens, Morgan Finlay, Fatima Menas, Ozlem Yildirim |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
782-I Phase I dose escalation of SAR445710, a PDL1-IL15 targeted cytokine in metastatic and/or advanced solid tumors
by: Jason Luke, et al.
Published: (2023-11-01) -
The Rapalogue, CCI-779, improves salivary gland function following radiation.
by: Maria Morgan-Bathke, et al.
Published: (2014-01-01) -
P779: Utility and diagnostic yield of prenatal skeletal dysplasia panel testing
by: Jay Shaw, et al.
Published: (2024-01-01) -
Survival at 11 to 21 years for 779 Metasul® metal-on-metal total hip arthroplasties
by: Roger Erivan, et al.
Published: (2020-06-01) -
The Interaction of TPH1 A779C Polymorphism and Maternal Authoritarianism on Creative Potential
by: Jinghuan Zhang, et al.
Published: (2018-11-01)